EMILY MAASS: Open Payments
NPI 1659925600 · RED OAK, IA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$580 in 35 payments from 13 companies in 2025. Trend: 2023 $639 · 2024 $838 · 2025 $580
Food & beverage: $580
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 13 | $160 |
| Novo Nordisk Inc | 4 | $72 |
| PFIZER INC. | 3 | $62 |
| Novartis Pharmaceuticals Corporation | 3 | $54 |
| AstraZeneca Pharmaceuticals LP | 2 | $38 |
| E.R. Squibb & Sons, L.L.C. | 2 | $35 |
| Actelion Pharmaceuticals US, Inc. | 1 | $30 |
| Phathom Pharmaceuticals, Inc. | 2 | $29 |
| Lundbeck LLC | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
Products named: MOUNJARO, LEQVIO, REXULTI, Ozempic, PREVNAR 20, CAMZYOS, OPSUMIT, VOQUEZNA.
Industry payments across IA — which companies pay providers there.
